Read Gene

Read Gene Net Change in Cash

The Net Change in Cash of Read Gene (RDG.WA) as of Nov 6, 2026 is -168,589.82 PLN. In the previous year, Net Change in Cash was 872,118.23 PLN — a change of -119.33% (lower).

Net Change in Cash

-168,589.82PLN

YoY

-119.33%

Last updated:

Net Change in Cash of Read Gene is 2025 -168,589.82 PLN. Net Change in Cash of Read Gene was 2024 872,118.23 PLN. It decreases by -119.33% lower compared to the previous year.

The Read Gene Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
1.34 M PLN
Jan 1, 2019
672,060.00 PLN
Jan 1, 2020
1.05 M PLN
Jan 1, 2021
44,006.57 PLN
Jan 1, 2022
104,060.63 PLN
Jan 1, 2023
-5.51 M PLN
Jan 1, 2024
872,118.23 PLN
Jan 1, 2025
-168,589.82 PLN
The Read Gene Net Change in Cash history
YEARNet Change in CashYoY
-168,589.82PLN-119.33%
872,118.23PLN-115.82%
-5.51 MPLN-5,397.24%
104,060.63PLN+136.47%
44,006.57PLN-95.81%
1.05 MPLN+56.29%
672,060.00PLN-49.97%
1.34 MPLN-2,786.40%
-50,000.00PLN-101.43%
3.49 MPLN+4,483.20%
76,200.00PLN-59.89%
190,000.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Net Change in Cash of Read Gene is -168,589.82 PLN in 2025.

Net Change in Cash of Read Gene changed from 872,118.23 PLN to -168,589.82 PLN, representing a -119.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Read Gene since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Read Gene

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Read Gene